Scynexis' (SCYX) Treatment of Invasive Aspergillus Infections Granted Orphan Drug Status by FDA

August 24, 2016 8:27 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Scynexis' (NASDAQ: SCYX) treatment of invasive aspergillus infections was granted orphan drug status by the FDA. The generic name is (1,3)-ß-D-glucan synthesis inhibitor.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment